Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Osmotica Pharmaceuticals Plc (OSMT)

Osmotica Pharmaceuticals Plc (OSMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 190,112
  • Shares Outstanding, K 51,521
  • Annual Sales, $ 263,700 K
  • Annual Income, $ -109,400 K
  • 60-Month Beta N/A
  • Price/Sales 0.72
  • Price/Cash Flow 1.17
  • Price/Book 0.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -4.99
  • Growth Rate Est. (year over year) +20,120.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +36.67%
on 08/23/19
3.80 -2.77%
on 09/12/19
+0.62 (+20.20%)
since 08/13/19
3-Month
2.70 +36.67%
on 08/23/19
4.30 -14.19%
on 07/09/19
+0.59 (+19.03%)
since 06/13/19

Most Recent Stories

More News
Osmotica Pharmaceuticals plc Announces Results of Extraordinary General Meeting

Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced results of the Company's Extraordinary General Meeting.

OSMT : 3.69 (-0.54%)
Osmotica Pharmaceuticals plc to Present at 2019 Wells Fargo Healthcare Conference

Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Andrew Einhorn, Chief Financial Officer, will present at the...

WFC : 48.92 (+0.55%)
OSMT : 3.69 (-0.54%)
Osmotica Pharmaceuticals plc Reports Second Quarter 2019 Results

Second quarter 2019 total revenue of $57.5 million

OSMT : 3.69 (-0.54%)
Osmotica Pharmaceuticals plc to Provide Second Quarter 2019 Business and Financial Update on August 8, 2019

Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 second quarter financial...

OSMT : 3.69 (-0.54%)
Shareholder Rights Law Firm Johnson Fistel Launches Investigations

Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims for violations of federal law against the following companies that recently issued stock in connection with an initial...

KZR : 3.52 (+3.53%)
STIM : 11.30 (-1.05%)
PT : 2.70 (+0.75%)
USX : 5.06 (-1.75%)
OSMT : 3.69 (-0.54%)
Osmotica Pharmaceuticals plc to Present at Jefferies 2019 Global Healthcare Conference

Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison, Chief Executive Officer, James "JD" Schaub,...

OSMT : 3.69 (-0.54%)
Osmotica Pharmaceuticals plc to Present at 2019 RBC Capital Markets Global Healthcare Conference

Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison, Chief Executive Officer, James "JD" Schaub,...

OSMT : 3.69 (-0.54%)
Osmotica Pharmaceuticals plc Reports First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress

First quarter 2019 total revenue of $57.1 million; net loss of $6.2 million

OSMT : 3.69 (-0.54%)
Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 ("RVL") for Acquired Blepharoptosis (ptosis or droopy eyelid)

- Second Phase III Study 202 Meets Primary Endpoint; Provides Additional Evidence of Efficacy and Safety -

OSMT : 3.69 (-0.54%)
Osmotica Pharmaceuticals plc to Provide First Quarter 2019 Business and Financial Update on May 9, 2019

Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 first quarter financial results...

OSMT : 3.69 (-0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade OSMT with:

Business Summary

Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women's health. The company's product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R)...

See More

Key Turning Points

2nd Resistance Point 3.82
1st Resistance Point 3.76
Last Price 3.69
1st Support Level 3.62
2nd Support Level 3.54

See More

52-Week High 9.90
Fibonacci 61.8% 6.96
Fibonacci 50% 6.05
Fibonacci 38.2% 5.14
Last Price 3.69
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar